Cognitive functioning in long-term survivors of high-grade glioma
The DOI matches its Crossref record.
Abstract
✓ In a pilot study, two groups of patients with malignant glioma underwent sequential neuropsychological evaluations after successful tumor treatment. Group 1 included nine patients treated from 1981 to 1985; all patients received irradiation and eight underwent chemotherapy. The baseline neuropsychological assessment was performed 1 to 63 months after tumor diagnosis, with follow-up evaluations at irregular intervals over the next 3 to 7 years. Six patients in Group 1 exhibited impairment on most measures at baseline; subsequently, two patients developed profound cognitive impairment. Initially, three patients functioned in the average range on most tasks; thereafter, two deteriorated on one measure each. Group 2 was ascertained prospectively and included 16 patients treated from 1985 to 1987, all of whom received irradiation and chemotherapy. The first evaluation was performed 18 months after diagnosis, then every 6 months for 2 years, and then yearly. Compared to a control group, those in Group 2 had significant cognitive impairment at baseline. Cognitive performance did not change over the next 12 months in 10 patients who remained free of tumor, but within 2 years of baseline testing, deterioration on specific tasks was evident in two of seven disease-free survivors. When last tested, five of six disease-free survivors had deteriorated on one or more measures. Unlike Group 1, severe global cognitive impairment was not seen, perhaps because Group 2 was followed for a shorter time. Verbal and nonverbal composite scores derived from intelligence quotient (IQ) tests showed less impairment at baseline than did other measures and were more likely to remain stable subsequently. Verbal memory and sustained attention were the most impaired at baseline, and verbal learning and flexibility in thinking showed the greatest tendency to decline over time. Cognitive functioning in survivors of high-grade glioma is best measured and monitored by tests that probe a broader spectrum of abilities than IQ. Neuropsychological measures used in this analysis lacked sensitivity at the lower end of the impaired range. Future studies should use tests better able to discern cognitive differences at low performance levels. Based on this experience, the authors conclude that most long-term survivors of high-grade glioma will have significant cognitive difficulties, usually evident by the first assessment; some patients will develop profound impairment years later, and few are capable of fully independent living.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Long-term survival with glioblastoma multiforme
Krex, D., Klink, B., Hartmann, C., von Deimling, A., Pietsch, T., Simon, M., Sabel, M., Steinbach, J. P., Heese, O., Reifenberger, G., et al. (2007) · Brain · doi:10.1093/brain/awm204 · Cited by 887
Cognitive deficits in adult patients with brain tumours
Taphoorn, M. J., & Klein, M. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00680-5 · Cited by 756
Cognitive Deficits before Treatment among Patients with Brain Tumors
Tucha, O., Smely, C., Preier, M., & Lange, K. W. (2000) · Neurosurgery · doi:10.1097/00006123-200008000-00011 · Cited by 398
Methylphenidate therapy improves cognition, mood, and function of brain tumor patients.
Meyers, C. A., Weitzner, M. A., Valentine, A. D., & Levin, V. A. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.7.2522 · Cited by 377
Leighton, C., Fisher, B., Bauman, G., Depiero, S., Stitt, L., MacDonald, D., & Cairncross, G. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1294 · Cited by 365
Self-citation5-ALA and FDA Approval for Glioma Surgery
Hadjipanayis, C. G., & Stummer, W. (2019) · Journal of Neuro-Oncology · doi:10.1007/s11060-019-03098-y · Cited by 338
Osoba, D., Aaronson, N. K., Muller, M., Sneeuw, K., Hsu, M. A., Yung, W. K. A., Brada, M., & Newlands, E. (1996) · Quality of Life Research · doi:10.1007/bf00435979 · Cited by 343
Shaw, E. G., Rosdhal, R., D'Agostino, R. B., Lovato, J., Naughton, M. J., Robbins, M. E., & Rapp, S. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.3001 · Cited by 326
ANDERSON-HANLEY, C., SHERMAN, M. L., RIGGS, R., AGOCHA, V. B., & COMPAS, B. E. (2003) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617703970019 · Cited by 302
Preoperative and postoperative cognitive functioning in patients with frontal meningiomas
Tucha, O., Smely, C., Preier, M., Becker, G., Paul, G. M., & Lange, K. W. (2003) · Journal of Neurosurgery · doi:10.3171/jns.2003.98.1.0021 · Cited by 295
Cognitive Function as a Predictor of Survival in Patients With Recurrent Malignant Glioma
Meyers, C. A., Hess, K. R., Yung, W. K. A., & Levin, V. A. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.3.646 · Cited by 271
Klein, M., . Taphoorn, M. J. B., Heimans, J. J., van der Ploeg, H. M., Vandertop, W. P., Smit, E. F., Leenstra, S., Tulleken, C. A. F., Boogerd, W., Belderbos, J. S. A., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.20.4037 · Cited by 259
Quality of life in adults with brain tumors: Current knowledge and future directions
Liu, R., Page, M., Solheim, K., Fox, S., & Chang, S. M. (2009) · Neuro-Oncology · doi:10.1215/15228517-2008-093 · Cited by 252
Butler, J. M., Case, L. D., Atkins, J., Frizzell, B., Sanders, G., Griffin, P., Lesser, G., McMullen, K., McQuellon, R., Naughton, M., et al. (2007) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.05.076 · Cited by 214
“Black 7 (21) 3 (9) White 26 (76) 31 (91) Other 1 ( 3 ) 0 (0)”
Metadata
- Authors
- Archibald, Y. M., Lunn, D., Ruttan, L. A., Macdonald, D. R., Del Maestro, R. F., Barr, H. W. K., Pexman, J. H. W., Fisher, B. J., Gaspar, L. E., & Cairncross, J. G.
- Venue
- Journal of Neurosurgery
- Published
- 1994-02
- Volume
- 80
- Issue
- 2
- Pages
- 247-253
- ISSN
- 0022-3085 (ISSN-L)
- OpenAlex
- W2032254273
- Cited by
- 157
- References
- 0
- FWCI
- 5.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.